Interferon-γ- and Glucocorticoid-mediated Pathways Synergize to Enhance Death of CD4(+) CD8(+) Thymocytes During Salmonella Enterica Serovar Typhimurium Infection
Overview
Affiliations
Thymic atrophy is known to occur during infections; however, there is limited understanding of its causes and of the cross-talk between different pathways. This study investigates mechanisms involved in thymic atrophy during a model of oral infection by Salmonella enterica serovar Typhimurium (S. typhimurium). Significant death of CD4(+) CD8(+) thymocytes, but not of single-positive thymocytes or peripheral lymphocytes, is observed at later stages during infection with live, but not heat-killed, bacteria. The death of CD4(+) CD8(+) thymocytes is Fas-independent as shown by infection studies with lpr mice. However, apoptosis occurs with lowering of mitochondrial potential and higher caspase-3 activity. The amounts of cortisol, a glucocorticoid, and interferon-γ (IFN-γ), an inflammatory cytokine, increase upon infection. To investigate the functional roles of these molecules, studies were performed using Ifnγ(-/-) mice together with RU486, a glucocorticoid receptor antagonist. Treatment of C57BL/6 mice with RU486 does not affect colony-forming units (CFU), amounts of IFN-γ and mouse survival; however, there is partial rescue in thymocyte death. Upon infection, Ifnγ(-/-) mice display higher CFU and lower survival but more surviving thymocytes are recovered. However, there is no difference in cortisol amounts in C57BL/6 and Ifnγ(-/-) mice. Importantly, the number of CD4(+) CD8(+) thymocytes is significantly higher in Ifnγ(-/-) mice treated with RU486 along with lower caspase-3 activity and mitochondrial damage. Hence, endogenous glucocorticoid and IFN-γ-mediated pathways are parallel but synergize in an additive manner to induce death of CD4(+) CD8(+) thymocytes during S. typhimurium infection. The implications of this study for host responses during infection are discussed.
Endogenous thymic regeneration: restoring T cell production following injury.
Granadier D, Acenas 2nd D, Dudakov J Nat Rev Immunol. 2025; .
PMID: 39762553 DOI: 10.1038/s41577-024-01119-0.
Kuo J, Wu H, Tung C, Huang W, Lin C, Wang C Chem Res Toxicol. 2024; 37(9):1488-1500.
PMID: 39141674 PMC: 11409377. DOI: 10.1021/acs.chemrestox.4c00060.
Primary and secondary defects of the thymus.
Dinges S, Amini K, Notarangelo L, Delmonte O Immunol Rev. 2024; 322(1):178-211.
PMID: 38228406 PMC: 10950553. DOI: 10.1111/imr.13306.
Thymus, undernutrition, and infection: Approaching cellular and molecular interactions.
Savino W, Duraes J, Maldonado-Galdeano C, Perdigon G, Mendes-da-Cruz D, Cuervo P Front Nutr. 2022; 9:948488.
PMID: 36225882 PMC: 9549110. DOI: 10.3389/fnut.2022.948488.
Bezlotoxumab prevents extraintestinal organ damage induced by infection.
Mileto S, Hutton M, Walton S, Das A, Ioannidis L, Ketagoda D Gut Microbes. 2022; 14(1):2117504.
PMID: 36045589 PMC: 9450906. DOI: 10.1080/19490976.2022.2117504.